Dyspareunia

Effectiveness of Combination of Tibolone and Lactobacilli Plus Lactoferrin in Postmenopausal Women with Vulvar Vestibular Pain: A Preliminary Report

BACKGROUND

Postmenopausal dyspareunia and vulvar pain are common complaints, affecting about 60% of women within a few years after hormone levels begin to decline (such as estrogen and androgen). Atrophic changes mainly located in the vulvar vestibule and vulnerability to vulvovaginal infections in postmenopause could be predisposing factors to the development of vulvar burning/pain and introital dyspareunia (vestibulodynia secondary to atrophy). Tibolone is the most effective and safe alternative for treating menopausal symptoms. The role of Lactobacilli and lactoferrin shows its effectiveness in the treatment of vaginal microbiota dysbiosis. The aim of the present study was to assess the efficacy of the combination of tibolone and an oral-specific Lactobacilli mixture in combination with bovine lactoferrin as synergistic therapy for the treatment of vestibulodynia related to atrophy.

METHODS

In this study, we included 35 postmenopausal women with at least 1 year of amenorrhea, affected by vulvar burning/pain and introital dyspareunia. All participants received treatment with open-label, oral Tibolone 2.5 mg and Lactobacilli mixture (5 × 109 CFU per capsule) in combination with bovine lactoferrin (Respecta®). Each product was taken once daily for 90 days.

RESULTS

After 90 d of therapy with TIB+ Respecta®, in 30 women that completed the treatment, there was a statistically significant decrease from the baseline in the mean of the Visual Analog Scale for vulvar burning/pain and a reduction in scores in the pain evaluation test.

CONCLUSIONS

This study provides evidence that the combination of TIB+ Respecta® was effective in reducing symptoms related to vestibular pain and hypersensitivity in a postmenopausal setting.

Prevalence of chronic pelvic pain and associated factors among indigenous women of reproductive age in Ecuador

BACKGROUND

Chronic pelvic pain is a common disease that affects approximately 4% of women of reproductive age in developed countries. This number is estimated to be higher in developing countries, with a significant negative personal and socioeconomic impact on women. The lack of data on this condition in several countries, particularly those in development and in socially and biologically vulnerable populations such as the indigenous, makes it difficult to guide public policies.

OBJECTIVES

To evaluate the prevalence of chronic pelvic pain (dysmenorrhea, dyspareunia, non-cyclical pain) and identify which variables are independently associated with the presence of the condition in indigenous women from Otavalo-Ecuador.

DESIGN

A cross-sectional study was carried out including a sample of 2429 women of reproductive age between 14 and 49 years old, obtained from April 2022 to March 2023. A directed questionnaire was used, collected by bilingual interviewers (Kichwa and Spanish) belonging to the community itself; the number of patients was selected by random sampling proportional to the number of women estimated by sample calculation. Data are presented as case prevalence, odds ratio, and 95% confidence interval, with p < 0.05.

RESULTS

The prevalence of primary dysmenorrhea, non-cyclic pelvic pain, and dyspareunia was, respectively, 26.6%, 8.9%, and 3.9%.all forms of chronic pain were independently associated with each other. Additionally, dysmenorrhoea was independently associated with hypertension, intestinal symptoms, miscegenation, long cycles, previous pregnancy, use of contraceptives and pear body shape. Pain in other sites, late menarche, exercise, and pear body shape were associated with non-cyclic pelvic pain. And, urinary symptoms, previous pregnancy loss, miscegenation, and pear body shape were associated with dyspareunia.

CONCLUSION

The prevalence of primary dysmenorrhea and non-cyclical chronic pelvic pain was notably high, in contrast with the frequency of reported dyspareunia. Briefly, our results suggest an association between dysmenorrhoea and conditions related to inflammatory and/or systemic metabolic disorders, including a potential causal relationship with other manifestations of pelvic pain, and between non-cyclical pelvic pain and signs/symptoms suggesting central sensitization. The report of dyspareunia may be influenced by local cultural values and beliefs.

Educational videos about dyspareunia and the assessment of their quality and reliability: An observational study

Objective:

The aim of this study was to analyze the characteristics, availability, quality and reliability of the information found in educational videos about dyspareunia.

Methods:

A systematic search was carried out on YouTube searching for educational videos about dyspareunia. Video quality scores were assessed with the DISCERN instrument, Global Quality Scale (GQS) and QUEST tool. Video popularity was evaluated with the Video Power Index (VPI). Interobserver agreement and statistical correlations of the assessment scores were also carried out.

Results:

The first 150 videos that appeared were selected. The mean number of views was 35,513.1 views (SD 71,443.9), the mean video length was 05:39 (SD 04:38), the mean days online was 1,396.3 days (SD 706), the mean view ratio was 29.8 (SD 68.1), the mean Like count was 333 likes (SD 1000.6), the mean Dislike count was 13 dislikes (SD 25.3) and the mean VPI Index was 92.1% (SD 16.4%). The mean values for the DISCERN instrument were for Observer-1 40.9 points (SD 9.9) and for Observer-2 39.3 points (SD 8.5). Mean values for the GQS score were for Observer-1 3.1 points (SD 0.9) and for Observer-2 3.0 points (SD 0.8). Finally, mean values for the QUEST tool were for Observer-1 13.3 points (SD 4.1) and for Observer-2 13.1 points (SD 4.2).

Conclusions:

The quality of the videos found on YouTube about dyspareunia, according to DISCERN, GQS, and QUEST scores, are average. Videos with high quality scores were produced by Academic Institutions, despite having lower frequency visit rates.

Extracorporeal shock wave therapy for treating dyspareunia: A prospective, randomized, double-blind, placebo-controlled study

BACKGROUND

Dyspareunia is a genital pain during or after penile-vaginal sexual intercourse. It is a painful spasm of the pelvic muscles that partly or entirely disables vaginal penetration.

OBJECTIVES

We examined the effect of extracorporeal shock wave therapy (ESWT) on idiopathic non-organic dyspareunia in women. A prospective, randomized, double-blind, placebo-controlled study was conducted.

METHODS

The study included 62 women who reported dyspareunia. Patients in the treatment and placebo groups received ESWT perineally weekly for 4 consecutive weeks; placebo patients received placebo stand-off treatment. The grade of dyspareunia was estimated by using the Marinoff Dyspareunia Scale and subjective pain intensity on a visual analog scale (VAS) before and after treatment. Follow-ups were conducted 1, 4 and 12 weeks after the final ESWT session.

RESULTS

The study included 61 women. The treatment but not placebo group differed by the Marinoff Dyspareunia Scale and VAS. Differences before and after treatment within groups were all P<0.001 and between groups, P<0.001. Pain reduction was always>30%. The effect sizes were both large: Marinoff 0.825 and VAS 0.883.

CONCLUSIONS

ESWT significantly reduced subjective pain in our women treated for dyspareunia.

Prevalence of dyspareunia and vulvodynia in a Colombian clinic sample: A pilot survey

Objective:

The primary objective of our research was to determine the prevalence of dyspareunia and vulvodynia in a limited clinical sample of Colombian women.

Methods:

The study was composed of women who were seen in local Colombian medical clinics. A pilot survey was designed in Spanish to obtain patients’ demographic and medical history. Harlow’s validated questionnaire was incorporated into our survey to screen for dyspareunia and vulvodynia.

Results:

Five hundred and eighty-two women completed the survey and 96.2% (N = 560) reported being sexually active. The survey response rate was 96%. Among those who were initially screened and reported being sexually active, 51.8% (N = 290; 95% confidence interval: 47.7%–55.9%) described having pain with intercourse (dyspareunia) and 25.9% (N = 145; 95% confidence interval: 22.4%–29.7%) did not have pain. Of those who were sexually active, Harlow’s validated questionnaire was completed by 490 women: 27.6% (N = 135; 95% confidence interval: 23.7–31.75) described vulvar pain lasting longer than 3 months (vulvodynia); 51.9% (95% confidence interval: 43.1%–60.5%) had burning pain; 42.4% (95% confidence interval: 33.8%–51.0%) had sharp stabbing pain; 69.6% (95% confidence interval: 61.1%–77.2%) reported having pain during intercourse (dyspareunia).

Conclusion:

In this select population sample, the prevalence of dyspareunia ranged from 51.8% using a general survey to 69.6% using a validated questionnaire. The prevalence of vulvodynia was 27.6% (95% confidence interval: 23.7–31.75). This is higher than the prevalence of dyspareunia (45%) and vulvodynia (3%–16%) reported in the US general population.

Evaluation and Treatment of Female Sexual Pain: A Clinical Review

Dyspareunia and vulvodynia are genital pain disorders that have devastating effects on women's quality of life. These disorders occur with high prevalence and place a significant financial burden on women and the health care system. Many women do not report genital pain, and most providers do not inquire about this type of pain. As a result, women also experience social isolation. Numerous treatments are thought to improve quality of life and decrease pain; however, more studies are needed. This review aims to provide an overview of clinical evaluation methods and to summarize treatment options for women suffering from dyspareunia and vulvodynia.

The relationship between fibromyalgia and pressure pain threshold in patients with dyspareunia

OBJECTIVE

To evaluate the number of tender points, pressure pain threshold and presence of fibromyalgia among women with or without dyspareunia.

METHODS

The present cross-sectional study included 40 patients with dyspareunia and 30 healthy controls. The participants were asked if they had engaged in sexual intercourse during the previous four weeks, and dyspareunia was rated from 0 to 3 based on the Marinoff Dyspareunia Scale. A pressure algometer (dolorimeter) was used to measure the pressure pain threshold. Fibromyalgia was diagnosed based on the 1990 American College of Rheumatology criteria. The depression status of the participants was assessed using the Beck Depression Inventory.

RESULTS

No statistically significant difference was found with regard to age, body mass index, habits (alcohol use and smoking), educational status and occupational status between the two groups. Total myalgic score, total control score and tender point mean pain threshold were significantly lower in the group with dyspareunia. The number of tender points was significantly higher in patients with dyspareunia. The mean Beck Depression Inventory score was 14.7±8.4 in the dyspareunia group compared with 11.2±7.1 in the control group. Five (12.5%) of the patients with dyspareunia were diagnosed with fibromyalgia, whereas no patients in the control group were diagnosed with fibromyalgia. There was no significant difference between the two groups with regard to the presence of fibromyalgia.

CONCLUSION

The finding of lower pressure pain thresholds and a higher number of tender points among patients with dyspareunia suggests that these patients may have increased generalized pain thresholds. Additional studies involving a larger number of patients are required to investigate the presence of central mechanisms in the pathogenesis of dyspareunia.

Vaginal epithelium and microflora characteristics in women with premature ovarian failure under hormone therapy compared to healthy women

PURPOSE

To evaluate some microbiological aspects of the vaginal flora and the vaginal trophism of women with premature ovarian failure (POF) in use of oral hormone therapy.

METHODS

A cross-sectional study with 36 women with POF under the age of 40 years using oral hormonal therapy. They were age matched with 36 women with normal gonadal function (control group). The characteristics of the vaginal epithelium were assessed through the hormonal vaginal cytology, vaginal pH measurement and vaginal health index to identify vaginal disturbances. Vaginal microflora was evaluated by the amine test, bacterioscopy (Nugent score) and culture for fungi to identify vaginal abnormal microflora and fungi infections.

RESULTS

Despite the fact that there were no statistical significant differences related to the cytological aspects and pH measurements, it was found that the vaginal health index was highly superior in the control group than in the POF group (23.4 ± 1.8 vs 20.8 ± 3.5), p < 0.0001 despite both groups had trophic scores. There were no statistical significance differences regarding to vaginal microflora types and fungi infection.

CONCLUSION

Oral hormone therapy for young women with POF seems to be good enough to reestablish the epithelium cells, vaginal pH and microflora.

Dyspareunia and its comorbidities among Taiwanese women: analysis of the 2004-2010 Nationwide Health Insurance Database

INTRODUCTION

Most of the existing studies on dyspareunia only focus on qualitative observations. These measurement tools may not reflect the actual situation of dyspareunia in Taiwan.

AIM

This study aimed to estimate the incidence of dyspareunia in Taiwan and investigate dyspareunia-associated comorbidities using the National Health Insurance Research Database (NHIRD).

METHODS

This study is a population-based retrospective cohort investigation.

MAIN OUTCOME MEASURES

We analyzed the 2004-2010 claims data on dyspareunia from the NHIRD. Dyspareunia was identified by outpatient visits using International Classification of Diseases, Ninth Revision, Clinical Modification (diagnosis code 6250). Patients who visited as outpatients with dyspareunia after the index date were considered to have comorbidities associated with dyspareunia medical conditions. The index events included vaginal disorders, vulvar disorders, uterine and ovarian factors, female genital organ and menstrual cycle disorders, menopause, and relative abdominopelvic organ disorders. The incidence of dyspareunia among different age groups was determined. The location and areas significantly related to the physical gynecology or relative pelvic organ causing the disease were also analyzed.

RESULTS

A total of 978 females of different ages had experienced dyspareunia. The incidence of dyspareunia was higher among individuals aged 30-34 years. The findings of this study indicated that dyspareunia was comorbid with menopause, pelvic floor dysfunction, and most gynecological infections. In particular, the more common physical causes of dyspareunia were introitus and vaginal infections (19.95%), menopause (16.80%), female genital organ and menstrual cycle disorders (15.22%), and female pelvic organ infections (13.65%).

CONCLUSIONS

This study posits that women of all ages (20-70 years) experience painful sexual intercourse. This large-scale nationwide claims-based study showed that menopause and pelvic infection disorder were dyspareunia-related comorbidities. Moreover, gynecological infections and pelvic floor dysfunctions were associated with dyspareunia.

Vaginal allodynia as the presentation of a thalamic tumor

Central pain syndromes associated with damage to the thalamic sensory relay nuclei have been described predominantly in the stroke literature; however, pain syndromes associated with thalamic neoplasms are much less common. We describe a woman with dyspareunia secondary to vaginal allodynia as the presenting sign of a left thalamic juvenile pilocytic astrocytoma. Subsequent to an uneventful stereotactic biopsy, her vaginal allodynia progressed to hemi-body allodynia. We believe that this is the first reported case of isolated vaginal allodynia associated with a thalamic neoplasm or any other structural pathology of the central nervous system. Dyspareunia secondary to vaginal allodynia as the presenting sign of a left thalamic juvenile pilocytic astrocytoma is reported, in a rare case underscoring that thalamic pathology including neoplasms should be considered in evaluating patients with longstanding and unexplained pain syndromes.

Self-reported vulvar pain characteristics and their association with clinically confirmed vestibulodynia

OBJECTIVE

We evaluated a series of questions pertaining to vulvar pain symptoms to determine their association with a localized vulvodynia (vestibulodynia) diagnosis in women from the general population.

METHODS

A sample of 12,435 women completed a self-administered screening questionnaire for the presence of specific types and characteristics of vulvar pain lasting 3 months or longer. Sensitivity, specificity, and predictive values were calculated for each cross-classification of vulvar pain type and characteristic, using as the gold standard 121 subjects with a clinically confirmed vestibulodynia diagnosis.

RESULTS

Relative to women with clinically confirmed vestibulodynia, 83% reported >10 episodes of pain on contact at the time of tampon insertion, intercourse, or pelvic examination, and 83% also reported pain on contact that limited or prevented sexual intercourse. These strong associations with a vestibulodynia diagnosis were not observed with respect to women who reported vulvar pain symptoms of burning or knifelike pain, or vulvar pain characteristics of continuous versus intermittent pain, or provoked versus spontaneous pain.

CONCLUSIONS

Our findings suggest that a small number of symptoms may be suitable for identifying a large proportion of women suffering from vestibulodynia which may be ideal for the development of an effective screening test in the future. However, we also recognize that a large proportion of women experiencing vulvar pain symptoms will not meet the diagnostic criteria for vestibulodynia. Thus, implementing such a screening procedure as part of a routine examination or testing would require a subsequent pelvic examination to confirm a vestibulodynia diagnosis and to rule out other known explanations for vulvar pain.

Dyspareunia in Puerto Rican middle-aged women

OBJECTIVE

Dyspareunia is a common sexual dysfunction. There is a lack of studies that address female sexual dysfunction in Puerto Rico. The present cross-sectional study characterized dyspareunia in a sample of Puerto Rican women aged 40 to 59 years and evaluated the relationship between reported dyspareunia with demographic, lifestyle, and health factors.

METHODS

Nine hundred twenty Puerto Rican women participated in health fairs conducted in 22 municipalities between May 2000 and November 2001 where they filled out a questionnaire. Contingency table and chi statistics were used to evaluate the bivariate associations of dyspareunia with demographic, lifestyle, and health factors. Crude and multivariate logistic regression models were used to estimate the magnitude of the association between dyspareunia and demographic, lifestyle, and health factors.

RESULTS

The overall prevalence of dyspareunia in this population was 18%. Dyspareunia was somewhat lower among women aged 40 to 49 years (17%) than among those aged 50 to 59 years (21%), not reaching statistical significance. Dyspareunia was associated with educational attainment, employment status, menopause status, current hormone therapy use, genitourinary symptoms, and loss of libido (P < 0.05). Current cigarette smoking, body mass index, physical activity, alcohol use, parity, and ever use of oral contraceptives were not associated with dyspareunia in bivariate analysis (P > 0.05). In the multivariate analysis, incontinence (prevalence odds ratio [POR], 1.67; 95% CI, 1.02-2.73), vaginal dryness (POR, 3.97; 95% CI, 2.49-6.31), vaginal itching (POR, 2.44; 95% CI, 1.55-3.83), loss of libido (POR, 3.08; 95% CI, 1.92-4.94), and partnership (POR, 2.22; 95% CI, 1.29-3.82) remained associated with dyspareunia.

CONCLUSIONS

Our results agree with previous studies regarding the potential association between health and lifestyle factors and dyspareunia. Additional studies of female sexual dysfunction in Puerto Rican women are highly warranted.

Sexuality during the climacteric period

BACKGROUND

Cultural, social, physiological and psychological factors may alter the course of sexual function in climacteric women.

OBJECTIVE

The objective of the present literature review is to survey the prevalence of sexual dysfunctions in the climacteric and to establish the association between the organic and psychic changes that occur during this phase and sexual dysfunction. We also discuss potential treatments.

METHODS

We evaluated the data available in PubMed (1982-2008). For each original article, two reviewers analyzed the data independently and considered a study to be of high quality if it had all three of the following characteristics: prospective design, valid data and adequate sample size. Both reviewers extracted data from each of the 99 studies selected: 34 cross-sectional studies, 25 cohort studies, 9 trials, 31 reviews related to sexuality in pre- and post-menopausal women.

RESULTS

Sexual dysfunction among climacteric women is widespread and is associated with bio-psychosocial factors. However, there is not enough evidence to correlate sexual dysfunction with a decrease in estrogen levels and biological aging. A strong association exists between climacteric genital symptoms and coital pain. There is, however, sufficient evidence demonstrating the benefits of local estrogen therapy for patients with genital symptoms.

CONCLUSION

A significant decline in sexual function occurs in climacteric women, although it is still unclear whether this is associated with the known decrease in estrogen levels or with aging, or both. Relational factors may interfere with sexual function during this phase. The climacteric genital symptoms improve with estrogen replacement therapy, and positively influence sexual function. Further studies are needed to establish the actual impact of the decrease in estrogen levels and of aging on the sex life of climacteric women.